Desmopressin acetate (DDAVP) for preventing and treating bleeding in people with mild or moderate haemophilia A
Referencias
Additional references
Castaman G, Mancuso ME, Giacomelli SH, Tosetto A, Santagostino E, Mannucci PM, et al. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. Journal of Thrombosis and Haemostasis 2009;7(11):1824‐31. [DOI: 10.1111/j.1538‐7836.2009.03595.x.]
Colucci G, Stutz M, Rochat S, Conte T, Pavicic M, Reusser M, et al. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood 2014;123(12):1905‐16. [DOI: 10.1182/blood‐2013‐04‐497123]
Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, et al. The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium. Haemophilia 2007;13(6):745‐9.
Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. Blood Coagulation and Fibrinolysis 2010;21(7):615‐9.
Giuffrida AC, Genesini S, Franchini M, De Gironcoli M, Aprili G, Gandini G. Inhibitors in mild/moderate haemophilia A: two case reports and a literature review. Blood Transfusion 2008;6(3):163‐8.
Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens‐Donadel S, et al. Factor VIII products and inhibitor development in severe hemophilia A. New England Journal of Medicine 2013;368(3):231‐9.
Hay CR. Factor VIII inhibitors in mild and moderate‐severity haemophilia A. Haemophilia 1998;4(4):558‐63.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ 2011;343:d5928.
Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo‐controlled crossover study. Haemophilia 2002;8(6):787‐93.
Karanth L, Barua A, Kanagasabai S, Nair NS. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD009824.pub3]
Leissinger C, Becton D, Cornell C, Cox Gill J. High‐dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001;7(3):258‐66.
Lethagen S, Harris AS, Sjörin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thrombosis and Haemostasis 1987;58(4):1033‐6.
Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. British Journal of Haematology 1981;47(2):283‐93.
Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90(7):2515‐21.
Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII‐deficient women. Blood 2005;105(8):3382.
Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders. www1.wfh.org/publication/files/pdf‐1131.pdf (accessed 24 September 2015).
Mauser‐Bunschoten EP, Den Uijl IE, Schutgens RE, Roosendaal G, Fischer K. Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia 2012;18(2):263‐7.
Miners A. Revisiting the cost‐effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A. Haemophilia 2009;15(4):881‐7.
Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non‐randomized studies. Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thrombosis and Haemostasis 1996;76(5):692‐6.
Srivastava A, Brewer AK, Mauser‐Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia 2012;19(1):e1‐47.
Sterne JAC, Higgins JPT, Reeves BC, on behalf of the development group for ACROBAT‐NRSI. A Cochrane risk of bias assessment tool: for non‐randomized studies of interventions (ACROBAT‐NRSI). www.riskofbias.info (accessed 01 October 2014); Vol. Version 1.0.0.
Stonebraker JS, Bolton‐Maggs PHB, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010;16(1):20–32.
Stonebraker JS, Brooker M, Amand RE, Farrugia A, Srivastava A. A study of reported factor VIII use around the world. Haemophilia 2010;16(1):33‐46.
